NLRP3 Inflammasome as Potential Predictor of Non-Responsiveness to Immunosuppressive Treatment in Lupus Nephritis
International Journal of Molecular Sciences · 19.12.2025 · 27 (1) · 43
DOI: 10.3390/ijms27010043 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.12.2025. Verfasst von Camila Barbosa Lyra de Oliveira und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Clinical Hospital, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Lupus Nephritis, Inflammasomes, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeicoamento de Pessoal de Nível Superior, Conselho Nacional de Pesquisa, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil.
Abstract (Originalsprache)
Lupus nephritis (LN) can affect up to 60% of patients with systemic lupus erythematosus (SLE). The NLRP3 inflammasome has been implicated in the pathogenesis of LN. This study aimed to evaluate the role of the NLRP3 inflammasome as a predictor of response to immunosuppressive treatment in patients with active LN. A prospective cohort study was conducted with 20 adult patients with active LN, classes III, IV, and V, from January 2021 to September 2023. Patients were followed up at biopsy (T0) and 6 months (T6) and 12 months (T12) after treatment and classified according to the primary efficacy renal response (PERR) at 12 months. Gene expression of NLRP3, CARD8, CASP1, IL1B, and IL18 was evaluated by RT-qPCR in PBMCs. Immunohistochemistry (IHC) for NLRP3 was performed on kidney tissue. The concentration of cytokine IL-1β was measured using the BD™ Cytometric Bead Array (CBA). The mean age was 31.9 ± 8.3 years, with 19 females and 1 male. After 12 months, 65% of patients achieved PERR. The IHC intensity in inflammatory cells was higher in patients with no PERR (p = 0.0426). In the no-PERR group, the gene expression of IL1B showed a significant increase at T6 (FC = 2.22: p = 0.0037) and T12 (FC = 2.91; p = 0.0001) compared with T0. Relative expression of IL1B was higher in no-PERR patients at T12 compared to the PERR group (p = 0.0477). The no-PERR group also had higher serum IL-1β levels compared to the PERR group at 12 months (2.9 ± 0.5 vs. 2.5 ± 0.7, p = 0.0164). In conclusion, our study evidenced an increase in IL1B expression and IL-1β levels over the 12 months of treatment in no-PERR patients, suggesting a potential biomarker of disease activity. Furthermore, a strong NLRP3 IHC staining score was associated with a higher likelihood of no PERR, highlighting the potential of the NLRP3 inflammasome as a predictor of worse clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Clinical Hospital, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
- Programa de Pós-Graduação em Biologia Aplicada à Saúde (PPGBAS), Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
- Institute Keizo Asami (iLIKA), Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
- Department of Oceanography, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
- Nephropathology Institute, Belo Horizonte 30150-281, Minas Gerais, Brazil.
- Agreste Science Center, Federal University of Pernambuco, Recife 50670-901, Pernambuco, Brazil.
ORCID-Profile: Werbson Lima Guaraná, Gisele Vajgel, Braziliano Miguel da Silva Júnior, Camilla Albertina Dantas Lima, Stanley de Almeida Araújo, Fabrício Oliveira Souto, Paula Sandrin-Garcia
Förderung
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- Conselho Nacional de Pesquisa
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil
- Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco
Zitieren
APA
Oliveira, C. B. L., Guaraná, W. L., Vajgel, G., Júnior, B. M. D. S., Lima, C. A. D., Araújo, S. A., Souto, F. O., Costa, D. M. D. N., Valente, L. M., & Sandrin-Garcia, P. (2025). NLRP3 Inflammasome as Potential Predictor of Non-Responsiveness to Immunosuppressive Treatment in Lupus Nephritis. International Journal of Molecular Sciences, 27(1), 43. https://doi.org/10.3390/ijms27010043
Vancouver
Oliveira CBL, Guaraná WL, Vajgel G, Júnior BMDS, Lima CAD, Araújo SA, et al. NLRP3 Inflammasome as Potential Predictor of Non-Responsiveness to Immunosuppressive Treatment in Lupus Nephritis. International Journal of Molecular Sciences. 2025;27(1):43. doi:10.3390/ijms27010043
BibTeX
@article{Oliveira2025,
author = {Oliveira, Camila Barbosa Lyra de and Guaraná, Werbson Lima and Vajgel, Gisele and Júnior, Braziliano Miguel da Silva and Lima, Camilla Albertina Dantas and Araújo, Stanley de Almeida and Souto, Fabrício Oliveira and Costa, Denise Maria do Nascimento and Valente, Lucila Maria and Sandrin-Garcia, Paula},
title = {NLRP3 Inflammasome as Potential Predictor of Non-Responsiveness to Immunosuppressive Treatment in Lupus Nephritis},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {27},
number = {1},
pages = {43},
doi = {10.3390/ijms27010043}
}
EUVIMED